Wisp review

Wisp: $225 a month, and there is no needle in it

Wisp's compounded weight product is sublingual semaglutide drops — 15mL, held under the tongue — at $225 a month, flat at every dose, medication included when it ships from Wisp's own pharmacy. It is the only compounded option Wisp sells. There is no compounded injectable, and no compounded tirzepatide in any form. That distinction gets lost constantly, because a price table has a column for semaglutide and no column for how it gets into you, and it is the first thing a mother comparing Wisp against the field needs to know.

Here is why it matters rather than being a footnote. Every weight-loss figure anyone quotes for semaglutide — the trial numbers, the year-one averages, the whole evidence base — comes from a weekly injection. Sublingual delivery of these peptides is a far less studied route, and absorption under the tongue is not the same problem as absorption from a subcutaneous depot. That does not make it useless. It makes it a convenience formulation rather than a proven equivalent, and at $225 against a ~$189 median for injectable programs, you are paying roughly the market rate for the less-evidenced version. If a needle is genuinely the thing standing between you and starting, that may be a trade worth making — with your eyes open, and with your own clinician's view on it.

The state list Wisp does publish — and the one it contradicts

Wisp's weight care is available in 26 states plus the District of Columbia, and it says so, in an FAQ on the product page itself: Alaska, California, Colorado, Delaware, DC, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Montana, Nebraska, Nevada, New York, North Dakota, Ohio, Oregon, Rhode Island, Utah, Vermont and Wyoming. Texas, Florida, Pennsylvania and Arizona are not on it. Anyone recording Wisp's coverage as "not disclosed" has not opened the right page.

The confusion is Wisp's own doing. Its general FAQ answers the question "Do you ship to all 50 US states?" with "Yes, we are able to prescribe medication in all 50 states!" — which is true of the wider catalogue of UTI, BV and contraception products, and not true of weight care. Two answers, one site, and only one of them applies to the thing you are buying. Check the product page, not the shipping page. Separately, nine states — Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island, Vermont and West Virginia — require a live video visit by law; everywhere else it stays asynchronous.

What you pay, and what the $99 is not

• Compounded sublingual semaglutide drops: $225/month, flat at every dose, medication and free delivery included
• Wegovy, Zepbound, Saxenda: listed at "$99/month" — this is Wisp's fee, not the pen; the drug is billed at your pharmacy on top
• Metformin: from about $24/month, framed explicitly for PCOS-related weight gain
• Insurance: not accepted for consults or prescriptions; HSA and FSA are, and a local-pickup co-pay can be billed
• Watch for: a $25 consult fee if a provider declines every treatment you asked for

That second line deserves a moment. A brand page headed "$99/ month" beside the word Zepbound reads, at a glance, like a $99 Zepbound — and the pen is nowhere near $99. Wisp's own wording is that it will "send your meds to your pharmacy—where additional costs may apply," which is doing a great deal of work in the phrase "may apply." Price the pharmacy, not the page.

The oversight is better than the category average

Wisp names its medical director — Dr. Shannon Chatham, DO, a board-certified family physician — and publishes a credentials page listing 26 clinicians with the number of state licences each holds. It discloses that its compounding pharmacy sits in Egg Harbor, New Jersey, and that it ships from eight pharmacies in total. It publishes a BMI threshold for the brand pens (27, or 25 for Asian and Pacific Islander patients). None of that is exotic, and all of it is more than most of the compounded field manages. The gap is that the pharmacy is located but never named, and that nothing anywhere describes a titration protocol, a follow-up cadence or a lab — care after the first prescription is "ongoing Care Team support," which is a phrase rather than a plan.

For a mother, one real strength and one strange silence

The strength: this is one account. Weight care sits beside the contraception, UTI and sexual-health lines a lot of women already use Wisp for, most of it asynchronous, none of it requiring a slot in a day that has none. And Wisp sells metformin from around $24 framed for PCOS-related weight gain, which is a cheap, genuinely well-studied option most of this masthead ignores entirely — worth reading alongside our piece on GLP-1s and PCOS.

The silence is odd. Wisp sells oral contraception and an oral GLP-1 and says nothing, anywhere, about how the two interact. There is no postpartum content and no breastfeeding guidance either — only a generic "if pregnant or nursing, consult your healthcare provider" line on the product pages. For a company built on women's reproductive health, that is a strange thing to leave to the customer. As with every GLP-1, none of this is for use during pregnancy or while breastfeeding.

The bottom line

Wisp earns its place here for one reason and it is a good one: a needle-free route, from a brand a lot of mothers already trust, with a named medical director behind it. Weigh that against what you give up — the less-studied sublingual formulation, a 26-state footprint that excludes four of the largest states in the country, no compounded tirzepatide, cash-pay only, and a cancellation you must email 48 hours ahead or it "will not be honored." If the injection is not the obstacle, the money buys more elsewhere: our #1 pick, CoreAge Rx, is nationwide, flat, and built around the conversation Wisp never has. Compare them head to head, or see the whole field in our best GLP-1 for women ranking.